Your session is about to expire
← Back to Search
Adavosertib for Cancer
Study Summary
This trial studies a drug called adavosertib to see how well it works in treating patients with SETD2-deficient solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 76 Patients • NCT02095132Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not on any cancer treatments except possibly LHRH analogues for over 6 months.I am a male willing to use condoms during the study and for 3 months after it ends.I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.I do not have active brain cancer or symptoms from previous brain metastases.Your liver enzymes (AST and ALT) are not more than three times the normal levels, or not more than five times the normal levels if you have liver metastases.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.I have advanced kidney cancer with a specific genetic change and have had previous treatment.I am not pregnant, not breastfeeding, and if able to bear children, I agree to use contraception during the study.I am willing and able to follow the study's requirements.My bilirubin levels are within the normal range, even with liver issues or Gilbert's syndrome.I cannot swallow pills and do not have a feeding tube or receive nutrition through an IV.I have been treated with a WEE1 inhibitor before.My cancer has spread, is not kidney cancer, and has a specific genetic change.My genetic test for SETD2 mutation will be reviewed by experts.I finished any radiation treatment at least a week ago and have recovered from its immediate side effects.I am not allergic to the study drug AZD1775.I am not taking any medication or herbal supplements that affect CYP3A4 enzymes.My kidney function, measured by creatinine levels or clearance, is within the required range.I am mostly active and can care for myself.You need to have at least 100,000 platelets per microliter of blood.I have not had serious heart problems in the last 6 months.I have experienced side effects worse than mild from previous treatments, excluding hair loss or loss of appetite.Your hemoglobin level is at least 9 grams per deciliter.I am not pregnant or breastfeeding.You have a disease that can be accurately measured using specific criteria.I haven't taken any cancer drugs in the last 3 weeks or within their half-life period before starting AZD1775.You have enough white blood cells called neutrophils.I finished my radiation therapy less than a week ago.
- Group 1: Treatment (adavosertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other research studies that have utilized Adavosertib?
"Currently, 17 trials related to Adavosertib are underway. None of which have progressed to Phase 3 yet, although a vast number of clinics and medical centres (1675) across the globe are involved in running these tests. The majority of these sites reside in Houston, Texas."
Are any participants currently being accepted for this research experiment?
"According to clinicaltrials.gov records, this trial is not in the process of recruiting at present. The study was originally posted on May 10th 2018 and last updated September 1st 2022; however, there are presently 4782 other active trials enrolling participants."
What is the aggregate size of the population participating in this clinical trial?
"At this time, the trial is no longer actively recruiting participants. Inception was May 10th 2018 and last edited on September 1st 2022. For those looking for other studies related to carcinoma, there are currently 4765 active trials available; moreover 17 clinical trials involving Adavosertib require participants as well."
What deleterious effects can be caused by taking Adavosertib?
"Our team at Power has rated Adavosertib's safety a 2, as there is only limited clinical data supporting its security. The Phase 2 trial does not yet have evidence of the drug's efficacy."
Are there plentiful Canadian facilities conducting this experiment?
"Patients are currently being recruited for this clinical trial at 16 different medical sites, such as University of Chicago Medicine-Orland Park in Orland Park, University of Pittsburgh Cancer Institute (UPCI) in Pittsburgh, and Johns Hopkins University/Sidney Kimmel Cancer Center in Baltimore."
Share this study with friends
Copy Link
Messenger